These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 35653195)
21. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism. Giammanco A; Spina R; Cefalù AB; Averna M Curr Atheroscler Rep; 2023 Mar; 25(3):67-76. PubMed ID: 36689070 [TBL] [Abstract][Full Text] [Related]
22. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Spagnuolo CM; Hegele RA Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828 [TBL] [Abstract][Full Text] [Related]
23. Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin. Pieke B; von Eckardstein A; Gülbahçe E; Chirazi A; Schulte H; Assmann G; Wahrburg U Int J Obes Relat Metab Disord; 2000 Oct; 24(10):1286-96. PubMed ID: 11093290 [TBL] [Abstract][Full Text] [Related]
24. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429 [No Abstract] [Full Text] [Related]
25. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717 [TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Tardif JC; Karwatowska-Prokopczuk E; Amour ES; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Hurh E; Bartlett VJ; Kingsbury J; Figueroa AL; Alexander VJ; Tami J; Witztum JL; Geary RS; O'Dea LSL; Tsimikas S; Gaudet D Eur Heart J; 2022 Apr; 43(14):1401-1412. PubMed ID: 35025993 [TBL] [Abstract][Full Text] [Related]
29. Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis. Kim S; Graham MJ; Lee RG; Yang L; Kim S; Subramanian V; Layne JD; Cai L; Temel RE; Shih D; Lusis AJ; Berliner JA; Lee S Nutr Metab Cardiovasc Dis; 2019 Mar; 29(3):306-315. PubMed ID: 30738642 [TBL] [Abstract][Full Text] [Related]
30. miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. Distel E; Barrett TJ; Chung K; Girgis NM; Parathath S; Essau CC; Murphy AJ; Moore KJ; Fisher EA Circ Res; 2014 Oct; 115(9):759-69. PubMed ID: 25201910 [TBL] [Abstract][Full Text] [Related]
31. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111 [TBL] [Abstract][Full Text] [Related]